Anti-Bevacizumab Antibodies
-
Bioanalytical Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
-
Our Anti-Biotherapeutic Antibodies
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Aflibercept Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Atezolizumab Antibodies
- Anti-Avelumab Antibodies
- Anti-Belatacept Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Obinutuzumab Antibodies
- Anti-Ocrelizumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Sarilumab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
-
Our Anti-Biotherapeutic Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
s
s
s
Antibodies for bioanalysis and drug monitoring of bevacizumab and biosimilars
Develop highly selective and sensitive PK assays for bevacizumab (Avastin) and ADA assays for bevacizumab and ranibizumab using our range of ready-made anti-idiotypic antibodies.
- Inhibitory antibodies specific to bevacizumab and ranibizumab
- Fully human surrogate positive control or calibrator
- Sequence defined, well characterized reagents with secure supply
- Recombinant production, stringent quality control for batch to batch consistency
- Non-animal-derived antibodies, reducing the use of animals in science
Table 1. Antibodies Specific to Bevacizumab and Ranibizumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Bevacizumab Inhibitory Type 1 |
HCA182 |
AbD17976 |
Fab-V5Sx21 |
0.4 |
PK bridging ELISA |
|
|
HCA184 |
AbD16748_hIgG1 |
hIgG1 HRP |
2.1 |
PK bridging ELISA |
||
|
Bevacizumab Ranibizumab2 Inhibitory Type 1 |
HCA185 |
AbD17976_hIgG1 |
hIgG1 |
0.4 |
ADA control |
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody, V5- and StrepX-StrepX- tags
2 Ranibizumab originates from the same parental mouse antibody as bevacizumab; it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab
Anti-Bevacizumab Inhibitory Antibodies (Type 1)
Type 1 anti-bevacizumab antibodies inhibit the binding of the drug bevacizumab to its target, vascular endothelial growth factor, VEGF. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibody in fully human IgG1 format is suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay for both bevacizumab and ranibizumab.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Bevacizumab PK bridging ELISA using antibodies HCA182 and HCA184P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
ADA Bridging ELISA
Fig. 2. Bevacizumab ADA bridging ELISA using antibody HCA185.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Fig. 3. Ranibizumab ADA bridging ELISA using HCA185.
Schematic image of ADA bridging assay. Monoclonal Fab fragment antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Related Products
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.